Clinical efficacy of S-1 in pretreated metastatic breast cancer patients

Japanese Journal of Clinical Oncology

Volumn 38, Issue 3, 2008, Pages 172-175

  Shien, Tadahiko ^a   Shimizu, Chikako ^a   Akashi Tanaka, Sadako ^a   Yonemori, Kan ^a   Kohno, Tsutomu ^a   Hojo, Takashi ^a   Ando, Masashi ^a   Katsumata, Noriyuki ^a   Kinoshita, Takayuki ^a   Fujiwara, Yasuhiro ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

Cancer; Chemotherapy; Metastatic breast; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; ANTHRACYCLINE; CAPECITABINE; CYCLOPHOSPHAMIDE; FLUOROURACIL; IRINOTECAN; METHOTREXATE; NAVELBINE; TAXANE DERIVATIVE; TRASTUZUMAB; UFT; ANTINEOPLASTIC ANTIMETABOLITE; OXONIC ACID; S 1 (COMBINATION); TEGAFUR; UNCLASSIFIED DRUG;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; LIVER DISEASE; METASTASIS POTENTIAL; MONOTHERAPY; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; RETROSPECTIVE STUDY; SOFT TISSUE METASTASIS; STOMATITIS; VISCERAL METASTASIS; VOMITING; BONE TUMOR; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; DRUG COMBINATION; METASTASIS; MIDDLE AGED; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; BONE NEOPLASMS; BREAST NEOPLASMS; DIARRHEA; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; HUMANS; MIDDLE AGED; NAUSEA; OXONIC ACID; RETROSPECTIVE STUDIES; TEGAFUR;

EID: 40749159653     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyn001     Document Type: Article

References (19)

1. Yap YS, Kendall A, Banerji U, Johnston SRD, Smith IE, O'Brien M. Clinical efficacy of capecitabine as first-line chemotherapy in metastatic breast cancer - How low can you go? Breast 2007;1:1-5.
2. Blum JL, Dees EC, Chacko A, Doane L, Ethirajan S, Hopkins J, et al. Phase II trial of capecitabine and weekly paclitaxel as firs-line therapy for metastatic breast cancer. Cancer 2001;24(27):4384-90.
3. Fumoleau P, Largillier R, Clippe C, et al. Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline-and taxane-pretreated metastatic breast cancer. Eur J Cancer 2004;40: 536-42.
4. Saeki T, Takashima S, Sano M, Horikoshi N, Miura S, Shimizu S, et al. A phase II study o f S-1 in patients with metastatic breast cancer - a Japanese trial by the S-1 Cooperative Study Group, Breast Cancer Working Group. Breast Cancer 2004;11:194-202.
5. Taira N, Aogi K, Ohsumi S, Takashima S, Nishimura R, Doihara H, et al. S-1 (TS-1) maintained complete response for approximately 10 years in a case of metastatic breast cancer. Breast Cancer 2006;13:220-4.
6. SakAta Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T. Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur -0.4 M gimestat- 1 M otastat potassium) in advanced gastric ct: patients. Eur J Cancer 1998;34:1715-20.
7. Kinoshita Nashimoto A, Yamamura Y, Okamura T, Sasako M, Sakamoto J, et al. Feasibility study of adjuvant chemotherap with S-1 (TS-1; tegafur, ginmeracil, oteracil potassium) for gastric cancer. Gastric Cancer 2004;7.104-9.
8. Koizumi W, Kurihara M, Nakano S, Hasegawa K. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology 2000;58:191-7.
9. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication No. 48. Geneva: World Health Organization 1979.
10. Fujiwara Y. Current status of oral anticancer drugs in Japan. J Clin Oncol 1999;17(10):3362-5.
11. Blum JL, Dieras V, Lo Russo PM, Horton J, Rutman O, Buzdar A, et al. Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. J Clin Oncol 2006;92(7):1759-68.
12. Lee SS, Lee JL, Ryu MH, Chang HM, Kim TW, Kang HJ, et al. Combination chemotherapy with capecitabine (x) and cisplatin (n) as first line treatincht in advanced gastric cancer: Experience of 223 patients with prognostic factor analysis. Jpn J Clin Oncol 2007;37(1):30-7.
13. Mackey JR, Tonkin KS, Koski SL, Scarfe AG, Smylie MG, Joy AA, et al. Final results of a phase II clinical trial of weekly docetaxel in combination with capecitabine in anthracycline-pretreated metastatic breast cancer. Clin Breast Cancer 2004;5(4):287-92.
14. Kellokumpu-Lehtinen PL, Sunela K, Lehtinen I, Joensuu H, Sjostrom-Mattson J. Finnish Breast Cancer Group. A phase I study of an all-oral combination of vinorelbine/capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and/or taxanes. Clin Breast Cancer 2006;7(5):401-5.
15. Welt A, Minckwitz GV, Oberhoff C, Borquez D, Schleucher R, Loihl S, et al. Phase I/II study of capecitabine and vinorelbine in pretreated. patients with metastatic breast cancer. Ann Oncol 2005;16:64-9.
16. O'Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol 2002;20:2812-23.
17. Oshaughnessy JA, Blum J, Moiseyenko V, Jones SE, Mies D, Bell D, et al. Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol 2001;12(9):1247-54.
18. Soto A, Kubota T, Fukushima M, Ikeda T, Takeshita T, Ohmiya H, et al. Antitumor effect of combination of S-1 and docetaxel on the human breast cancer xenograft transplanted into SCID mice. Oncol Rep 2006;15(6):1517-22.
19. Nukatsuka M, Fujioka A, Nakagawa F, Oshimo H, Kitazato K, Uchida J, et al. Antimetastatic and anticancer activity of S-1, a new oral dihydropyrimidine-dohydrogenase-inhibiting fluoropyrimidine, alone and in combination with paclitaxel in an orthotopically implanted human breast cancer model. Int J Oncol 2004;25(6):1531-6.